AG˹ٷ

STOCK TITAN

[Form 4] Biogen Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

SEC Form 4 filed on 06/18/2025 reveals that Biogen Inc. (BIIB) director Susan K. Langer acquired 2,370 shares of common stock on 06/17/2025. The transaction is coded “A,� indicating an acquisition, and carries a stated price of $0 per share, characteristic of a director equity grant rather than an open-market purchase. Following the award, Langer’s direct beneficial ownership rises to roughly 5,129 shares. No derivative security activity or additional transactions were reported. The filing was signed by attorney-in-fact Wendell Taylor on behalf of the director. No other material changes or footnotes accompany the filing.

Il modulo SEC Form 4 presentato il 18/06/2025 rivela che Susan K. Langer, direttrice di Biogen Inc. (BIIB) ha acquisito 2.370 azioni ordinarie il 17/06/2025. La transazione è contrassegnata con il codice “A�, che indica un'acquisizione, e riporta un prezzo dichiarato di 0 $ per azione, tipico di una concessione azionaria a un direttore piuttosto che di un acquisto sul mercato aperto. Dopo l'assegnazione, la proprietà diretta di Langer aumenta a circa 5.129 azioni. Non sono state segnalate attività su titoli derivati né altre transazioni aggiuntive. Il modulo è stato firmato dall’avvocato Wendell Taylor per conto della direttrice. Non sono presenti ulteriori modifiche rilevanti o note a margine.

El formulario SEC Form 4 presentado el 18/06/2025 revela que Susan K. Langer, directora de Biogen Inc. (BIIB) adquirió 2,370 acciones comunes el 17/06/2025. La transacción está codificada como “A�, indicando una adquisición, y muestra un precio declarado de $0 por acción, característico de una concesión de acciones para un director en lugar de una compra en el mercado abierto. Tras la adjudicación, la propiedad directa de Langer aumenta aproximadamente a 5,129 acciones. No se reportaron actividades con valores derivados ni transacciones adicionales. La presentación fue firmada por el apoderado Wendell Taylor en nombre de la directora. No hay otros cambios materiales ni notas adicionales en la presentación.

2025� 6� 18� 제출� SEC 양식 4� 따르�, Biogen Inc.(BIIB) 이사 Susan K. Langer가 2025� 6� 17일에 보통� 2,370주를 취득했습니다. 거래� 인수(A)� 분류되었으며, 주당 0달러� 명시되어 있어 공개 시장에서� 매입� 아닌 이사 주식 부여임� 나타냅니�. 수여 � Langer� 직접 소유 주식 수는 � 5,129주로 증가했습니다. 파생 증권 활동이나 추가 거래� 보고되지 않았습니�. � 서류� 이사� 대신하� 법률 대리인 Wendell Taylor가 서명했습니다. 기타 중요� 변� 사항이나 주석은 없습니다.

Le formulaire SEC Form 4 déposé le 18/06/2025 révèle que Susan K. Langer, administratrice de Biogen Inc. (BIIB) a acquis 2 370 actions ordinaires le 17/06/2025. La transaction est codée « A », indiquant une acquisition, avec un prix déclaré de 0 $ par action, caractéristique d’une attribution d’actions à un administrateur plutôt que d’un achat sur le marché libre. Après cette attribution, la détention directe de Langer s’élève à environ 5 129 actions. Aucune activité sur titres dérivés ni transaction supplémentaire n’a été signalée. Le dépôt a été signé par l’avocat mandaté Wendell Taylor au nom de l’administratrice. Aucun autre changement matériel ni note n’accompagne ce dépôt.

Das am 18.06.2025 eingereichte SEC Formular 4 zeigt, dass Susan K. Langer, Direktorin von Biogen Inc. (BIIB), am 17.06.2025 2.370 Stammaktien erworben hat. Die Transaktion ist mit dem Code „A� für Erwerb gekennzeichnet und weist einen angegebenen Preis von 0 $ pro Aktie auf, was typisch für eine Aktienzuteilung an einen Direktor und nicht für einen Kauf am offenen Markt ist. Nach der Zuteilung steigt Langers direkter Besitz auf etwa 5.129 Aktien. Es wurden keine Aktivitäten mit derivativen Wertpapieren oder weitere Transaktionen gemeldet. Die Einreichung wurde vom Bevollmächtigten Wendell Taylor im Namen der Direktorin unterzeichnet. Weitere wesentliche Änderungen oder Anmerkungen sind nicht enthalten.

Positive
  • Director insider acquisition: Susan Langer obtained 2,370 BIIB shares, expanding direct ownership to ~5,129 and signaling continued alignment with shareholders.
Negative
  • None.

Insights

TL;DR � Small share award modestly increases director stake; marginally positive governance signal.

Insider activity remains one of many qualitative indicators for investors. While the 2,370-share grant boosts Susan Langer’s holdings by about 86% (to ~5,129 shares), the absolute value is minor relative to Biogen’s ~145 million-share float. Still, a net increase—rather than a sale—leans positive, suggesting ongoing alignment of board incentives with shareholder interests. No options, sales, or complex derivative positions were disclosed, reducing concerns about near-term dilution or conflicting signals. Overall, the event is directionally positive but not financially material; portfolio managers may log it as supportive but insufficient on its own to alter an investment thesis.

Il modulo SEC Form 4 presentato il 18/06/2025 rivela che Susan K. Langer, direttrice di Biogen Inc. (BIIB) ha acquisito 2.370 azioni ordinarie il 17/06/2025. La transazione è contrassegnata con il codice “A�, che indica un'acquisizione, e riporta un prezzo dichiarato di 0 $ per azione, tipico di una concessione azionaria a un direttore piuttosto che di un acquisto sul mercato aperto. Dopo l'assegnazione, la proprietà diretta di Langer aumenta a circa 5.129 azioni. Non sono state segnalate attività su titoli derivati né altre transazioni aggiuntive. Il modulo è stato firmato dall’avvocato Wendell Taylor per conto della direttrice. Non sono presenti ulteriori modifiche rilevanti o note a margine.

El formulario SEC Form 4 presentado el 18/06/2025 revela que Susan K. Langer, directora de Biogen Inc. (BIIB) adquirió 2,370 acciones comunes el 17/06/2025. La transacción está codificada como “A�, indicando una adquisición, y muestra un precio declarado de $0 por acción, característico de una concesión de acciones para un director en lugar de una compra en el mercado abierto. Tras la adjudicación, la propiedad directa de Langer aumenta aproximadamente a 5,129 acciones. No se reportaron actividades con valores derivados ni transacciones adicionales. La presentación fue firmada por el apoderado Wendell Taylor en nombre de la directora. No hay otros cambios materiales ni notas adicionales en la presentación.

2025� 6� 18� 제출� SEC 양식 4� 따르�, Biogen Inc.(BIIB) 이사 Susan K. Langer가 2025� 6� 17일에 보통� 2,370주를 취득했습니다. 거래� 인수(A)� 분류되었으며, 주당 0달러� 명시되어 있어 공개 시장에서� 매입� 아닌 이사 주식 부여임� 나타냅니�. 수여 � Langer� 직접 소유 주식 수는 � 5,129주로 증가했습니다. 파생 증권 활동이나 추가 거래� 보고되지 않았습니�. � 서류� 이사� 대신하� 법률 대리인 Wendell Taylor가 서명했습니다. 기타 중요� 변� 사항이나 주석은 없습니다.

Le formulaire SEC Form 4 déposé le 18/06/2025 révèle que Susan K. Langer, administratrice de Biogen Inc. (BIIB) a acquis 2 370 actions ordinaires le 17/06/2025. La transaction est codée « A », indiquant une acquisition, avec un prix déclaré de 0 $ par action, caractéristique d’une attribution d’actions à un administrateur plutôt que d’un achat sur le marché libre. Après cette attribution, la détention directe de Langer s’élève à environ 5 129 actions. Aucune activité sur titres dérivés ni transaction supplémentaire n’a été signalée. Le dépôt a été signé par l’avocat mandaté Wendell Taylor au nom de l’administratrice. Aucun autre changement matériel ni note n’accompagne ce dépôt.

Das am 18.06.2025 eingereichte SEC Formular 4 zeigt, dass Susan K. Langer, Direktorin von Biogen Inc. (BIIB), am 17.06.2025 2.370 Stammaktien erworben hat. Die Transaktion ist mit dem Code „A� für Erwerb gekennzeichnet und weist einen angegebenen Preis von 0 $ pro Aktie auf, was typisch für eine Aktienzuteilung an einen Direktor und nicht für einen Kauf am offenen Markt ist. Nach der Zuteilung steigt Langers direkter Besitz auf etwa 5.129 Aktien. Es wurden keine Aktivitäten mit derivativen Wertpapieren oder weitere Transaktionen gemeldet. Die Einreichung wurde vom Bevollmächtigten Wendell Taylor im Namen der Direktorin unterzeichnet. Weitere wesentliche Änderungen oder Anmerkungen sind nicht enthalten.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LANGER SUSAN

(Last) (First) (Middle)
225 BINNEY

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/17/2025 A 2,370 A $0 5,129.1 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Wendell Taylor, attorney-in-fact for Susan K. Langer 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Biogen (BIIB) shares did director Susan Langer acquire?

2,370 common shares were acquired on 06/17/2025.

What is Susan Langer’s total direct ownership after the transaction?

Her holdings rose to approximately 5,129 shares according to the Form 4.

Was the transaction an acquisition or a sale?

It was an acquisition (Transaction Code “A�).

What price was reported for the acquired shares?

The filing states a $0 per-share price, typical of an equity award.

When was the Form 4 for Biogen filed and signed?

It was signed on 06/18/2025 by attorney-in-fact Wendell Taylor for Susan Langer.
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

18.60B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE